{
    "clinical_study": {
        "@rank": "41992", 
        "arm_group": [
            {
                "arm_group_label": "Study Drug Level 1", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Study Drug Level 2", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is designed to evaluate the effectiveness of 2 doses of pregabalin to reduce\n      seizure frequency as an add on therapy in pediatric subjects 1 month to <4 years of age with\n      refractory partial onset seizures. It is hypothesized that both doses of pregabalin will\n      demonstrate superior efficacy when compared to placebo by reducing the partial onset seizure\n      frequency and that pregabalin will be safe and well tolerated."
        }, 
        "brief_title": "A Safety, Efficacy, and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric Subjects <4 Years of Age With Partial Onset Seizures.", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Partial Onset Seizures", 
        "condition_browse": {
            "mesh_term": "Seizures"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject must have 3 partial onset seizures in the month prior to screening.\n\n          -  Subject must have 2 partial onset seizures during the 48 hour baseline phase.\n\n          -  Signed Informed Consent.\n\n          -  On 1-3 stable anti-epileptic drugs at screening.\n\n        Exclusion Criteria:\n\n          -  Primary generalized seizures including clonic, tonic, clonic-tonic, absence, febrile\n             seizures, and infantile spasms.\n\n          -  Lennox-Gasteau, BECTS, and Dravet's syndrome.\n\n          -  Status epliepticus within 1 year of screening.\n\n          -  Any change in AED regimen with 7 days of screening.\n\n          -  Progressive structural central nervous system (CNS) lesion or a progressive\n             encephalopathy.\n\n          -  Progressive errors of metabolism."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "3 Years", 
            "minimum_age": "1 Month"
        }, 
        "enrollment": {
            "#text": "123", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 25, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02072824", 
            "org_study_id": "A0081042"
        }, 
        "intervention": [
            {
                "arm_group_label": "Study Drug Level 1", 
                "description": "Pregabalin liquid dosed daily three times a day in equally divided doses escalated to 7.0 mg/kg/day beginning at Randomization through Taper Phase then tapered to 3.5 mg/kg/day during 1 week Taper Phase", 
                "intervention_name": "Pregabalin Dose Level 1", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Study Drug Level 2", 
                "description": "Pregabalin liquid dosed daily three times a day in equally divided doses escalated to 14.0 mg/kg/day beginning at Randomization through Taper Phase then tapered to 3.5 mg/kg/day during 1 week Taper Phase", 
                "intervention_name": "Pregabalin Dose Level 2", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo Liquid dosed three times daily beginning at Randomization through Taper Phase", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Pregabalin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Partial Onset Seizures", 
            "Epilepsy", 
            "Safety", 
            "Efficacy", 
            "Tolerability", 
            "Pregabalin", 
            "Lyrica", 
            "Adjunctive treatment", 
            "Placebo controlled", 
            "blinded", 
            "Eligibility Criteria"
        ], 
        "lastchanged_date": "May 19, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A0081042&StudyName=A%20Safety%2C%20Efficacy%2C%20and%20Tolerability%20Trial%20of%20Pregabalin%20as%20Add-On%20Treatment%20in%20Pediatric%20Subjects%20%3C4%20years%20of%20age%20with%20Partial%20"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "San Antonio", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "78258"
                }, 
                "name": "Road Runner Research"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Double-blind, Placebo-controlled, Parallel-group, Multicenter Study of the Efficacy and Safety of Pregabalin As Adjunctive Therapy in Children 1 Month Through <4 Years of Age With Partial Onset Seizures", 
        "overall_contact": {
            "last_name": "Pfizer CT.gov Call Center", 
            "phone": "1-800-718-1021"
        }, 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Percent reduction of partial onset seizures during the double-blind assessment phase, collected by video-EEG recording.", 
            "measure": "Percent reduction of 24 hour seizure rate for all partial onset seizures relative to placebo during the double-blind assessment phase.", 
            "safety_issue": "No", 
            "time_frame": "Video-EEG recordings for a target minimum of 48 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02072824"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "The proportion of subjects who have at least a 50% reduction in 24 hour partial onset seizure rate during the double-blind assessment phase, as measured from baseline (data collected during the 48 hour baseline video-EEG phase).", 
            "measure": "Responder rate, defined as the proportion of subjects who had at least a 50% reduction in 24 hour partial onset seizure rate.", 
            "safety_issue": "No", 
            "time_frame": "calculated from 48 hour basline through the 2 week double-blind treatment phase"
        }, 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}